ClinicalTrials.gg
CompletedNCT02641028Updated Apr 27, 2025

A Study in a Human Laboratory Model of Smoking Behavior

A Phase 2 interventional study of CERC-501 and Placebo in Smoking, sponsored by Janssen Research & Development, LLC. Completed at 3 sites in United States. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 899 studies in Smoking with a site in United States — 90 open to participants now, 110 under way, 4 of them phase 3. Smoking · United States.

Enrollment
481st of 785
71 · median 109
Started
2015
with 42 others
Phase 2
75 of 899
10 open now
Registered
500th of 899
by date

Among the 899 studies in Smoking with a site in United States, this one is the 481st largest by enrollment of the 785 interventional ones that give a count, is one of 43 that started in 2015, is one of 75 in phase 2, and was the 500th registered.

Smoking

1,513 studies on the registry are indexed under Smoking; 196 are open to participants now.

Browse Smoking studies →

Open to participants now

90 of the 899 studies in Smoking with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 143 Smoking studies recruiting now, 74 (52%) set no upper age limit and 51 (36%) stop at 75 or younger; 3 take children under 18; 67 take healthy volunteers.

This study: 21 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 899 studies in Smoking with a site in United States, or all of them as a file.
02

Study summary

A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior.

Read the detailed description

The study will be performed in subjects who are heavy cigarette smokers currently not seeking treatment for tobacco use disorder.

The study is a crossover design study (within-subject analysis), which allows for subjects to be their own control.

Each period of the crossover consists of a 7-day out-patient treatment period followed by a single in-patient testing day on Day 8. Subjects will participate in a laboratory session following the McKee Smoking Lapse Test and be discharged from the clinic to undergo a 7 day washout period followed by the second period of the crossover design and a 7-day follow-up visit.

03

Conditions studied

  • Smoking

Browse trials for

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provides written and agrees to complete required clinic visits
  2. Male or female 21 to 60 years of age inclusive
  3. (BMI) 18.5 to 40 kg/m2 inclusive
  4. Heavy Smokers
  5. Currently not seeking smoking cessation therapy
  6. In otherwise good general health without any unstable medical conditions (as determined by medical history, medication history, physical examination, 12-lead , vital signs, and clinical laboratory testing)
  7. Able to read, write, and speak in English
  8. Females must be either:

    • (amenorrhea for at least 12 consecutive months), surgically sterile -or-
    • Women of (WOCBP) must meet the criteria below:

      • Uses an acceptable double-barrier method of as determined by the Investigator -and-
      • Is not lactating, has a negative serum beta human chorionic gonadotropin pregnancy test at screening and a negative urine pregnancy test prior to dosing on Days 1 and 8 of each treatment period.
  9. Male subjects must agree to use a condom if partner is of childbearing potential

Exclusion criteria

Exclusion Criteria:

Subjects meeting the following criteria are not eligible for the study:

  1. Any substance use disorder other than nicotine or caffeine as assessed by the , Fifth Edition (DSM-V) substance use disorder checklist in addition to the Mini-International Neuropsychiatric Interview (MINI) (to capture both DSM-V substance use disorder diagnoses)
  2. Current neurological conditions that interfere with study conduct, assessment or treatment in any significant fashion
  3. Any lifetime history of bipolar I, II; schizophrenia or any other psychotic disorders; personality disorders, impulse control disorders as assessed by the MINI
  4. Current psychiatric conditions that interfere with study conduct, assessment or treatment in any significant fashion, such as major depressive disorder (MDD), eating disorders, post-traumatic stress disorder, etc., without permission of the medical monitor
  5. Recent active or past history of gastric disease such as peptic ulcer disease, gastritis, upper gastrointestinal bleeding, or any gastrointestinal or precancerous condition
  6. Active, comorbid disease that might limit the ability of the subject to participate in the study as determined by the Investigator (i.e., poorly controlled diabetes mellitus, congestive heart failure, etc.)
  7. clinical laboratory test taken during screening, without permission of the Medical Monitor
  8. Elevated or ALT ≥ 2 times the (ULN)
  9. (HIV), or positive as determined by serology testing at Screening
  10. History of severe allergies or multiple adverse drug reactions
  11. Known to CERC-501
  12. Current use of a proton pump inhibitor or histamine 2 blocker without permission of the Medical Monitor
  13. Use of any medication within 2 months prior to the start of this study or scheduled to receive an investigational drug other than the study drug during the course of this study
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    CERC-501

    Administered orally once daily, 15mg daily, 8 days.

    Drug: CERC-501

  • Placebo comparator
    Placebo

    Administered orally daily, 8 days.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Latency

    Latency (in minutes and seconds) to time of first cigarette smoked during the delay period

    Time frame: 50 min

  2. Number of Cigarettes smoked

    Number of cigarettes smoked during the self administration period

    Time frame: 60 min

Secondary outcomes

  1. Tobacco Craving

    Tobacco craving assessed by the Tiffany Questionnaire of Smoking Urges-Brief (QSU-Brief) prior to tobacco withdrawal (Day 7 of each Period) and prior to reinstatement of tobacco (Day 8 of each period)

    Time frame: Up to 4 days ( 2 each period)

  2. Mood Scores

    Mood Scores (Circumplex) prior to tobacco withdrawal (Day 7 of each Period) and prior to reinstatement of tobacco (Day 8 of each period)

    Time frame: Up to 4 days ( 2 each period)

  3. Nicotine Withdrawal

    Nicotine withdrawal scores will be assessed by the Minnesota Nicotine Withdrawal Scale (MNWS) prior to tobacco withdrawal (Day 7 of each Period) and prior to reinstatement of tobacco (Day 8 of each period)

    Time frame: Up to 4 days ( 2 each period)

  4. Anxiety Scores

    Anxiety Scores will be assessed by the Clinically Useful Depression Outcome Scale Modified for Anxious distress (CUDOS-A) prior to tobacco withdrawal (Day 7 of each Period) and prior to reinstatement of tobacco (Day 8 of each period)

    Time frame: Up to 4 days ( 2 each period)

  5. Subject Feeling

    Subject feelings of positive and negative effect of tobacco as assessed by the Modified Cigarette Evaluation Questionnaire (mCEQ) prior to tobacco withdrawal (Day 7 of each Period) and prior to reinstatement of tobacco (Day 8 of each period)

    Time frame: Up to 4 days ( 2 each period)

  6. Electronic Diary

    Daily Smoking Diary for out-patient periods

    Time frame: up to 51 days

07

Study locations

3 sites
  • Vince and Associates
    Overland Park, Kansas 66212, United States
  • University of Kentucky
    Lexington, Kentucky 40508, United States
  • Columbia University
    New York, New York 10032, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Sep 2016, 8 months.

Of 22 phase 2 interventional studies under Smoking, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 62. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2015
First posted
Dec 29, 2015
StartActual
Dec 31, 2015
Primary completionActual
Sep 13, 2016
CompletionActual
Dec 31, 2016
Results delay requested
Sep 18, 2017
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02641028
Responsible party
Sponsor
First posted
Dec 29, 2015
Start date
Dec 31, 2015
Primary completion
Sep 13, 2016
Completion
Dec 31, 2016
Last update
Apr 27, 2025

Study contacts

Ronald Marcus, MD
study director · Avalo Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aticaprant

Start the discussion